MedTrace Logo

ClearWay Rx Readmission Registry

NCT01673893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2018-11-29

Study results available
· View outcomes & findings →

Summary

The purpose of this registry is to determine if delivery of weight adjusted, in a large dose with either Abcixmab or Eptifibitide through the ClearWay™ RX, in patients admitted for primary coronary intervention lowers readmission rate. This is done in comparison to the historical control of the Medicare/Medicaid readmission database. The registry will record the use of the product during the index procedure, and determine whether or not the patient was readmitted within 30 days, related to the index procedure.

Conditions

  • Acute Myocardial Infarction

Interventions

DEVICE

ClearWay™ Rx catheter

Sponsors & Collaborators

  • Cardiovascular Institute of the South Clinical Research Corporation

    lead OTHER

Principal Investigators

  • Nick Cavros, MD · Cardiovascular Institute of the South

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673893 on ClinicalTrials.gov